E-LIB Suche - Ergebnisse für: Reda, G.

1

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thr..:

Oliva E. N ; Riva M ; Niscola P...
info:eu-repo/semantics/altIdentifier/pmid/37294914. , 2023

Link: https://hdl.handle.net/1..

2

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients..:

Zamprogna G ; Frustaci A. M ; Travi G...
info:eu-repo/semantics/altIdentifier/pmid/37153871. , 2023

Link: https://hdl.handle.net/1..

3

Efficacy of Front-Line Ibrutinib and Rituximab Combination ..:

Mauro F. R ; Paoloni F ; Molica S...
info:eu-repo/semantics/altIdentifier/pmid/35008372. , 2022

Link: https://hdl.handle.net/1..

4

Efficacy of Front-Line Ibrutinib and Rituximab Combination ..:

Mauro F. R ; Paoloni F ; Molica S...
info:eu-repo/semantics/altIdentifier/pmid/35008372. , 2022

Link: http://hdl.handle.net/11..

5

Coexisting conditions and concomitant medications do not af..:

Frustaci A. M ; Del Poeta G ; Visentin A...
info:eu-repo/semantics/altIdentifier/pmid/36246422. , 2022

Link: https://hdl.handle.net/1..

6

Efficacy of Front-Line Ibrutinib and Rituximab Combination ..:

Mauro F. R ; Paoloni F ; Molica S...
info:eu-repo/semantics/altIdentifier/wos/WOS:000771433100001. , 2022

Link: http://hdl.handle.net/11..

7

Efficacy of Front-Line Ibrutinib and Rituximab Combination ..:

Mauro F. R ; Paoloni F ; Molica S...
info:eu-repo/semantics/altIdentifier/pmid/35008372. , 2022

Link: http://hdl.handle.net/11..

8

Efficacy of Front-Line Ibrutinib and Rituximab Combination ..:

Mauro F. R ; Paoloni F ; Molica S...
info:eu-repo/semantics/altIdentifier/pmid/35008372. , 2022

Link: https://hdl.handle.net/1..

9

Thrombotic and bleeding complications in patients with chro..:

Antic D ; Milic N ; Chatzikonstantinou T...
info:eu-repo/semantics/altIdentifier/pmid/36028857. , 2022

Link: http://hdl.handle.net/11..

10

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocy..:

Puzzolo M. C ; Del Giudice I ; Peragine N...
info:eu-repo/semantics/altIdentifier/pmid/33937038. , 2021

Link: https://hdl.handle.net/1..

11

COVID-19 severity and mortality in patients with CLL: an up..:

Chatzikonstantinou T ; Kapetanakis A ; Scarfo L...
info:eu-repo/semantics/altIdentifier/pmid/34725454. , 2021

Link: http://hdl.handle.net/11..

12

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (..:

Garcia-Manero, G ; Santini, V ; Almeida, A...
issn:0732-183X. , 2021

Link: http://hdl.handle.net/11..

13

Prognostic impact and risk factors of infections in patient..:

Mauro F. R ; Giannarelli D ; Visentin A...
info:eu-repo/semantics/altIdentifier/pmid/34209515. , 2021

Link: http://hdl.handle.net/23..

14

Comparison of ibrutinib and idelalisib plus rituximab in re..:

Morabito F ; Tripepi G ; Del Poeta G...
info:eu-repo/semantics/altIdentifier/pmid/33378569. , 2021

Link: https://hdl.handle.net/1..

15

Comparison of ibrutinib and idelalisib plus rituximab in re..:

Morabito F ; Tripepi G ; Del Poeta G...
info:eu-repo/semantics/altIdentifier/pmid/33378569. , 2021

Link: http://hdl.handle.net/24..